Morgan Stanley Maintains Equal-Weight on Contineum Therapeutics, Lowers Price Target to $17

Benzinga Newsdesk www.benzinga.com Neutral 49.1%

Neg 0% Neu 49.1% Pos 0%

Morgan Stanley analyst Jeffrey Hung maintains Contineum Therapeutics (NASDAQ:CTNM) with a Equal-Weight and lowers the price target from $18 to $17.